It was found that the tumor size of YTHDF1 knockout mice is much smaller than that of wild type, and the immunoreactivity of M6A knockout mice was stronger than that of wild type [41], indicating that YTHDF1 can be used as an important target of immunotherapy against clinical tumors. Here, METTL3 is linked to neoplasm.